Literature DB >> 15596227

Effects of dehydroepiandrosterone on ovarian cystogenesis and immune function.

Carolina Griselda Luchetti1, Maria Emilia Solano, Valeria Sander, Maria L Barreiro Arcos, Claudio Gonzalez, Guillermo Di Girolamo, Sara Chiocchio, Graciela Cremaschi, Alicia B Motta.   

Abstract

The purpose of the present report was to study the possible relationship between ovarian functionality and the immune response during cystogenesis induced by androgenization with dehydroepiandrosterone (DHEA). Daily injection of DHEA (6 mg/kg body weight) for 20 consecutive days induced ovarian cysts in BALB/c mice. As markers of ovarian function, serum estradiol (E) and progesterone (P) and the ovarian inmunomodulator prostaglandin E (PGE) were analyzed. In order to know how the integrity of the tissue was altered after induction of cystogenesis, the oxidative status was also evaluated. Serum E and P levels, and ovarian PGE concentration, were increased in animals with cysts compared with healthy controls. The oxidant status (quantified by malondialdehyde (MDA) formed after the breakdown of the cellular membrane by free radical mechanisms) was augmented, meanwhile the antioxidant (evaluated by the glutathione (GSH) content) diminished during the induction of cystogenesis. Both immunohistochemical and flow cytometry assays demonstrated that DHEA treatment increased the number of T lymphocytes infiltrating ovarian tissue. Therefore, while ovarian controls showed equivalent expression of CD4+ and CD8+ T cell subsets, injection of DHEA yielded a selective ovarian T cell infiltration as demonstrated by enhanced CD8+ and diminished CD4+ T lymphocyte expression. These results show that the development of cysts involves changes in ovarian function and an imbalance in the oxidant-antioxidant equilibrium. We observed also both an increased and selective T lymphocyte infiltration.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15596227     DOI: 10.1016/j.jri.2004.04.002

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  27 in total

1.  High levels of testosterone inhibit ovarian follicle development by repressing the FSH signaling pathway.

Authors:  Tao Liu; Yu-Qian Cui; Han Zhao; Hong-Bin Liu; Shi-Dou Zhao; Yuan Gao; Xiao-Li Mu; Fei Gao; Zi-Jiang Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-10-22

2.  Low-Dose Dihydrotestosterone Drives Metabolic Dysfunction via Cytosolic and Nuclear Hepatic Androgen Receptor Mechanisms.

Authors:  Stanley Andrisse; Shameka Childress; Yaping Ma; Katelyn Billings; Yi Chen; Ping Xue; Ashley Stewart; Momodou L Sonko; Andrew Wolfe; Sheng Wu
Journal:  Endocrinology       Date:  2017-03-01       Impact factor: 4.736

3.  Starting and resulting testosterone levels after androgen supplementation determine at all ages in vitro fertilization (IVF) pregnancy rates in women with diminished ovarian reserve (DOR).

Authors:  Norbert Gleicher; Ann Kim; Andrea Weghofer; Aya Shohat-Tal; Emanuela Lazzaroni; Ho-Joon Lee; David H Barad
Journal:  J Assist Reprod Genet       Date:  2012-12-05       Impact factor: 3.412

4.  Dehydroepiandrosterone and metformin regulate proliferation of murine T lymphocytes.

Authors:  M E Solano; V Sander; M R Wald; A B Motta
Journal:  Clin Exp Immunol       Date:  2008-06-28       Impact factor: 4.330

5.  Diet-induced obesity may affect the uterine immune environment in early-mid pregnancy, reducing NK-cell activity and potentially compromising uterine vascularization.

Authors:  V J Parker; M E Solano; P C Arck; A J Douglas
Journal:  Int J Obes (Lond)       Date:  2013-09-04       Impact factor: 5.095

Review 6.  The role of androgens in follicle maturation and ovulation induction: friend or foe of infertility treatment?

Authors:  Norbert Gleicher; Andrea Weghofer; David H Barad
Journal:  Reprod Biol Endocrinol       Date:  2011-08-17       Impact factor: 5.211

7.  Prenatal hyperandrogenization induces metabolic and endocrine alterations which depend on the levels of testosterone exposure.

Authors:  Sabrina Amalfi; Leandro Martín Velez; María Florencia Heber; Susana Vighi; Silvana Rocío Ferreira; Adriana Vega Orozco; Omar Pignataro; Alicia Beatriz Motta
Journal:  PLoS One       Date:  2012-05-24       Impact factor: 3.240

8.  Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome.

Authors:  Irene Tessaro; Silvia C Modina; Federica Franciosi; Giulia Sivelli; Laura Terzaghi; Valentina Lodde; Alberto M Luciano
Journal:  J Ovarian Res       Date:  2015-10-06       Impact factor: 4.234

9.  The mechanism of mTOR (mammalian target of rapamycin) in a mouse model of polycystic ovary syndrome (PCOS).

Authors:  Aylin Yaba; Necdet Demir
Journal:  J Ovarian Res       Date:  2012-11-27       Impact factor: 4.234

10.  The estrogen-injected female mouse: new insight into the etiology of PCOS.

Authors:  John C Chapman; Soo Hong Min; Steven M Freeh; Sandra D Michael
Journal:  Reprod Biol Endocrinol       Date:  2009-05-18       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.